- Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies
- First Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments
- FIRST LIGHT ACQUISITION GROUP, INC. Further Adjourns Special Meeting of Stockholders to August 28, 2023 at 10:30 am ET
- FIRST LIGHT ACQUISITION GROUP, INC. Adjourns Special Meeting of Stockholders to August 24, 2023 at 10:30 am ET
- Flag Stockholders: Reminder to Vote for Proposed Business Combination
- First Light Acquisition Group, Inc. Announces Effectiveness of Registration Statement and Sets August 22, 2023 as Date of Stockholder Meeting for the Calidi Business Combination
More ▼
Key statistics
On Friday, Calidi Biotherapeutics Inc (CLDI:ASQ) closed at 0.2275, 58.54% above the 52 week low of 0.1435 set on Apr 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.25 |
---|---|
High | 0.252 |
Low | 0.22 |
Bid | 0.221 |
Offer | 0.235 |
Previous close | 0.242 |
Average volume | 406.70k |
---|---|
Shares outstanding | 50.92m |
Free float | 16.09m |
P/E (TTM) | -- |
Market cap | 11.59m USD |
EPS (TTM) | -0.6154 USD |
Data delayed at least 15 minutes, as of May 17 2024 21:10 BST.
More ▼